» Articles » PMID: 37580334

Bacteroides Uniformis-induced Perturbations in Colonic Microbiota and Bile Acid Levels Inhibit TH17 Differentiation and Ameliorate Colitis Developments

Overview
Date 2023 Aug 14
PMID 37580334
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel disease (IBD) is associated with gut dysbiosis and can lead to colitis-associated malignancies. Bacteroides uniformis (Bu) regulates animal intestinal homeostasis; however, the mechanism by which it alleviates colitis in mice remains unknown. We investigated the effects of B. uniformis JCM5828 and its metabolites on female C57BL/6J mice with dextran sulfate sodium salt (DSS) induced colitis. Treatment with Bu considerably alleviated colitis progression and restored the mechanical and immune barrier protein expression. Additionally, Bu increased the abundance of the symbiotic bacteria Bifidobacterium and Lactobacillus vaginalis while decreasing that of pathogenic Escherichia-Shigella, and modulated intestinal bile acid metabolism. Bu largely regulated the expression of key regulatory proteins of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways in colonic tissues and the differentiation of TH17 cells. However, Bu could not directly inhibit TH17 cell differentiation in vitro; it modulated the process in the lamina propria by participating in bile acid metabolism and regulating key metabolites (alpha-muricholic, hyodeoxycholic, and isolithocholic acid), thereby modulating the intestinal immune response. Our findings suggest that Bu or bile acid supplements are potential therapies for colitis and other diseases associated with intestinal barrier dysfunction.

Citing Articles

Selective utilization of medicinal polysaccharides by human gut Bacteroides and Parabacteroides species.

Qu Z, Liu H, Yang J, Zheng L, Huang J, Wang Z Nat Commun. 2025; 16(1):638.

PMID: 39809740 PMC: 11733155. DOI: 10.1038/s41467-025-55845-7.


Correlation Between Gastroesophageal Reflux Disease and Small Intestinal Bacterial Overgrowth: Analysis of Intestinal Microbiome and Metabolic Characteristics.

Wang Z, Tan W, Huang J, Zhang P, Li Q, Wang M J Inflamm Res. 2025; 18():33-51.

PMID: 39780983 PMC: 11708204. DOI: 10.2147/JIR.S487185.


Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.

Bai S, Chandnani A, Cao S Biomedicines. 2025; 12(12).

PMID: 39767816 PMC: 11673883. DOI: 10.3390/biomedicines12122910.


Regulation of bile acids and their receptor FXR in metabolic diseases.

Li Y, Wang L, Yi Q, Luo L, Xiong Y Front Nutr. 2024; 11:1447878.

PMID: 39726876 PMC: 11669848. DOI: 10.3389/fnut.2024.1447878.


Dynamic Shifts in Antibiotic Residues and Gut Microbiome Following Tilmicosin Administration to Silkie Chickens.

Liang Q, Xie C, Gebreselase H, Yuan Y, He J, Xie L Animals (Basel). 2024; 14(23).

PMID: 39682393 PMC: 11640304. DOI: 10.3390/ani14233428.


References
1.
Ng S, Bernstein C, Vatn M, Lakatos P, Loftus Jr E, Tysk C . Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013; 62(4):630-49. DOI: 10.1136/gutjnl-2012-303661. View

2.
Molodecky N, Soon I, Rabi D, Ghali W, Ferris M, Chernoff G . Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2011; 142(1):46-54.e42. DOI: 10.1053/j.gastro.2011.10.001. View

3.
Chen Y, Zhang L, Hong G, Huang C, Qian W, Bai T . Probiotic mixtures with aerobic constituent promoted the recovery of multi-barriers in DSS-induced chronic colitis. Life Sci. 2019; 240:117089. DOI: 10.1016/j.lfs.2019.117089. View

4.
Lu Q, Yang M, Liang Y, Xu J, Xu H, Nie Y . Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics. J Inflamm Res. 2022; 15:1825-1844. PMC: 8928114. DOI: 10.2147/JIR.S353038. View

5.
Ni J, Wu G, Albenberg L, Tomov V . Gut microbiota and IBD: causation or correlation?. Nat Rev Gastroenterol Hepatol. 2017; 14(10):573-584. PMC: 5880536. DOI: 10.1038/nrgastro.2017.88. View